Skip to content
Successful trial of an artificial pancreas in patients with type 2 diabetes

Successful trial of an artificial pancreas in patients with type 2 diabetes

Successful trial of an artificial pancreas in patients with type 2 diabetes

A artificial pancreasmade up of an algorithm-driven device, for people with type 2 diabetes doubled the time spent in a target glucose range and halved the time spent at high levels, compared to standard treatment.

Some 415 million people suffer from type 2 diabetes in the world, which represents a annual health spending of US$760 billionrecalls the study from the University of Cambridge and published in the journal “Nature Medicine”.

Type 2 diabetes causes glucose – blood sugar – levels to be too high and is treated with a combination of lifestyle changes, with the goal of keeping glucose levels low.

Very well received prototype

The artificial pancreas combines a conventional glucose monitor and insulin pump with an app developed by the team, which runs on an algorithm that predicts how much insulin is needed to keep glucose levels in target range.

The study reports on the results of the first trial for eight weeks with a group of 26 people who did not need kidney dialysis and who were divided into two groups. One half first tried the device and then continued with the usual treatment, and the other the other way around.

The team used several measures to assess the effectiveness of the artificial pancreas. The first was the proportion of time patients spent with glucose levels within a target range.

On average, the patients who used the artificial pancreas spent two-thirds (66%) of the time within that interval, double that of the other group (32%).

A second measure was the proportion of time they had elevated glucose levels. Those who continued in usual treatment spent two thirds (67%) of the time, a percentage that was reduced to 33% with the artificial pancreas.

Feedback from participants suggested that they were satisfied that the system automatically monitored glucose levels, and nine out of ten (89%) said they spend less time managing their diabetes overall.

Key benefits included not having to inject and increased confidence in blood glucose control. The disadvantages were the increased anxiety given the risk of hypoglycemia and the practical inconvenience derived from the use of the devices.

An artificial pancreas driven by a similar algorithm had already been shown to be effective for patients with type 1 diabetes and in patients with type 2 who require dialysis. The researchers plan to conduct a larger multicenter study. In addition, they have submitted this device for regulatory approval for outpatient marketing.

Source: Elcomercio

Share this article:
globalhappenings news.jpg
most popular